28 Декабрь,2002 | Острые эндогенные психозы - Пападопулос Т.Ф.
Острые эндогенные психозы - Пападопулос Т.Ф.
26 Декабрь,2002 | HUMAN SCHIZOPHRENIA GENE
Abstract: Nucleic acids comprising the neuregulin 1 gene and encoding NRG1 polypeptides are disclosed. European Patents via NewsEdge Corporation : Abstract: Nucleic acids comprising the neuregulin 1 gene (NRG1) and encoding NRG1 polypeptides are disclosed. Also described are related nucleic acids encoding NRG1 polypeptides; NRG1 polypeptides; antibodies that bind to NRG1 polypeptides; methods of diagnosis of susceptibility to schizophrenia; assays for agents that alter the activity of NRG1 polypeptide or which identify NRG1 binding agents, and the agents or binding agents identified by the assays; NRG1 therapeutic agents, including the NRG1 nucleic acids, NRG1 polypeptides, or agents that alter the activity of an NRG1 polypeptides; pharmaceutical compositions comprising the NRG1 therapeutic agents; as well as methods of therapy of schizophrenia. Pub. No.: EP 1265999 Appl. Data: EP 01913147 2001 02 28 If you would like to purchase a copy of this patent, please call MicroPatent at 800-648-6787. Applicant: Decode Genetics EHF. << Copyright ©2002 MicroPatent >>
21 Декабрь,2002 | Autism cases show increase
Barbara Bibbo' 12/21/2002 Autism is affecting an increasing number of children in the UAE, despite greater attention and new measures taken by the local authorities to stem the problem, said local experts. Gulf News via NewsEdge Corporation : Barbara Bibbo' 12/21/2002 Autism is affecting an increasing number of children in the UAE, despite greater attention and new measures taken by the local authorities to stem the problem, said local experts. The disability which about 10 years ago in the UK was affecting 10 children in 10,000, is today detected in 63 out of 10,000, and the trend in the UAE is likely to mimic the international increase. According to Dr Derrick Smith, psychiatrist at the University of British Columbia, currently visiting the UAE, the increase is not only due to higher awareness about autism which contributes to detecting a bigger number of cases, but to a probable increase in the spectrum of the risk factors which scientific researches are trying to bring to surface. Although the UAE has no official studies on the incidence of autism in the country, an increased number of cases has led to the opening of five new centres in the last two years, a local expert added. Dr Mowafaq Mustafa, Deputy Director of the Abu Dhabi Future Centre, which hosts some patients, said that increased attention by the UAE authorities is contributing to dispel the confusion and ignorance about the disability, which was prevalent just two years ago. "Many centres have been opened in the last two years to treat autistic patients, including the Sharjah and Dubai centres for Autism, the Abu Dhabi Red Crescent's centre, the Abu Dhabi Sheikha Shamsa's centre and the Abu Dhabi Educational Zone Centre. "Knowledge about the disease is increasing but more has to be done to help these patients, since behavioural treatment which is very long and expensive is to date the only effective way to stem the problem." Speaking on the sidelines of a conference on autism the two specialists said the UAE could have a number of cases which remain undetected, since the disability is easily misdiagnosed. The conference was sponsored by Sheikh Nahyan bin Mubarak Al Nahyan, Minister of Higher Education and Scientific Research and honourary president of the Future Centre. "Autistic children reveal a wide spectrum of symptoms including attention deficit, social interaction problems, communication difficulties, in some cases hyperactivity and delay in the motor skills." Dr Smith added: "The main cause is genetic, but many other factors can contribute to the disorder to reveal itself like exposure to radiations, viral infections during pregnancy, lack of oxygen during childbirth, meningitis, brain infection, and others. Nevertheless, in many cases the cause remains unknown." According to him detection of the disability is often delayed, because the symptoms are mistaken for bad social behaviour. Patients are blamed of abnormal social conduct or mental retardation and this jeopardises their capability of playing a role in society forever. "Early detection and intensive behavioural treatment can help the patients to run almost a normal life, although they will never recover completely. Behavioural therapy is very long and expensive, requiring a one to one interaction with a therapist and up to 40 hours a week exercise with the patients." Dr Smith, who is in the UAE on a special visit to promote awareness, also assessed some cases. He announced the preparation of a visit by some international experts to be in the UAE in February next year to continue the awareness campaign on the disability. Copyright 2002. All Rights Reserved. Financial Times Information Limited - Asia Africa Intelligence Wire <> << Copyright ©2002 Financial Times Limited, All Rights Reserved >>
19 Декабрь,2002 | Wyeth's Effexor XR significantly relieves physical and emotional symptoms of depression and generalized anxiety disorder.
12/11/2002 Wyeth Pharmaceuticals announced that the serotonin-norepinephrine reuptake inhibitor antidepressant Effexor XR significantly relieved patients' physical and emotional symptoms related to depression and generalized anxiety disorder , according to data presented at an annual scientific meeting of neuropsychopharmacologists. Chemical Business NewsBase - Press Release via NewsEdge Corporation : 12/11/2002 Wyeth Pharmaceuticals announced that the serotonin-norepinephrine reuptake inhibitor antidepressant Effexor XR (venlafaxine HCl) significantly relieved patients' physical and emotional symptoms related to depression and generalized anxiety disorder (GAD), according to data presented at an annual scientific meeting of neuropsychopharmacologists. Effexor XR is believed to increase levels of both serotonin and norepinephrine, two of the brain chemicals thought to be implicated in depression and generalized anxiety disorders. Effexor XR was significantly effective in treating GAD patients' physical and emotional symptoms and equally effective regardless of the initial severity of physical symptoms, according to three pooled analyses of 1841 GAD patients in five double-blinded studies. Moreover, 767 GAD patients treated with Effexor XR and followed for six months demonstrated continued improvement across the spectrum of symptoms beyond their first eight weeks of therapy. Also, in depression patients, Effexor XR demonstrated greater therapeutic effect than selective serotonin reuptake inhibitors fluoxetine, paroxetine, and fluoxamine regardless of the severity of physical and emotional symptoms, according to two other pooled analyses of eight randomised, double-blind studies in 2045 patients. Patients with untreated or under-treated depression and GAD may suffer from an array of physical (somatic) and emotional (psychic) symptoms. Effexor XR was discovered and developed by Wyeth Pharmaceuticals, the pharmaceutical division of Wyeth. The product is also marketed by Wyeth Pharmaceuticals. The immediate-release formulation was approved by the FDA in 1993; the extended-release (XR) formulation was approved in 1997. These medications are available only by prescription. Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, cardiovascular disease, central nervous system, inflammation, haemophilia, oncology and vaccines. Copyright 2002. All Rights Reserved. Financial Times Information Limited - Asia Africa Intelligence Wire <> << Copyright ©2002 Financial Times Limited, All Rights Reserved >>
18 Декабрь,2002 | Warning that diet pills can lead to depression, suicide
12/18/2002 Overweight people have been warned that using diet pills containing amphetamine agents can cause depression and even lead to suicide. Bangkok Post via NewsEdge Corporation : 12/18/2002 Overweight people have been warned that using diet pills containing amphetamine agents can cause depression and even lead to suicide. Dr Apichai Mongkol, deputy director-general of the Mental Health Department, said shedding kilos by taking diet pills with methamphetamine substances for a long time would badly affect one's health. Side-effects of the pills included sleeping problems, loss of appetite and a lack of serotonin, which could lead to depression and even suicide, he added. There were no statistics on the number of people suffering mental illnesses from taking diet pills as people did not divulge this to psychiatrists, he said. About 1% of the Thai population of 62 million suffers from mental problems of some sort. Dr Apichai suggested overweight people set themselves clear goals to lose 2kg a year, and reward themselves occasionally by eating a favourite food, instead of using diet pills. Public Health Minister Sudarat Keyuraphan said the recent death of a diet-pill user in Ang Thong was a lesson for teenagers and women who resorted to medication to lose weight. The use of diet pills should be closely monitored by doctors or it could be harmful since such medicines affected the nervous system as well, she said. Mrs Sudarat called on those with weight problems to exercise for 30 minutes at least three times a week, and eat more fruit and vegetables instead of sweet and fatty food. Food and Drug Administration deputy secretary-general Dr Sathaporn Wongcharoen said diet pills were dangerous because they contained amfepramone, phentermine, mazindol and cathine which affected the central nervous system and could cause coronary diseases in the long run. Copyright 2002. All Rights Reserved. Financial Times Information Limited - Asia Africa Intelligence Wire <> << Copyright ©2002 Financial Times Limited, All Rights Reserved >>
17 Декабрь,2002 | PROTEIN AND GENE AND THEIR USE FOR DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA
Abstract: The present invention provides methods and compositions for screening, diagnosis and prognosis of Schizophrenia, for monitoring the effectiveness of Schizophrenia treatment, identifying patients most likely to respond to a particular therapeutic treatment and for drug development. European Patents via NewsEdge Corporation : Abstract: The present invention provides methods and compositions for screening, diagnosis and prognosis of Schizophrenia, for monitoring the effectiveness of Schizophrenia treatment, identifying patients most likely to respond to a particular therapeutic treatment and for drug development. Schizophrenia-Associated Features (SFs), detectable by two- dimensional electrophoresis of cerebrospinal fluid, serum or plasma are described. The invention further provides Schizophrenia-Associated Protein Isoforms (SPIs) detectable in cerebrospinal fluid, serum or plasma, preparations comprising isolated SPIs, antibodies immunospecific for SPIs, and kits comprising the aforesaid. Pub. No.: EP 1259607 Appl. Data: EP 01909957 2001 02 23 If you would like to purchase a copy of this patent, please call MicroPatent at 800-648-6787. Applicant: Oxford GlycoSciences (UK) Limited << Copyright ©2002 MicroPatent >>
17 Декабрь,2002 | New data suggest Risperdal (risperidone) can produce symptom relief when used alone to treat bipolar mania.
12/10/2002 In a new study, individuals with bipolar disorder experienced significant relief of manic symptoms when treated with Risperdal . The research was presented for the first time at a major US psychiatry meeting. Chemical Business NewsBase - Press Release via NewsEdge Corporation : 12/10/2002 In a new study, individuals with bipolar disorder (also known as manic depression) experienced significant relief of manic symptoms when treated with Risperdal (risperidone). The research was presented for the first time at a major US psychiatry meeting. The multi-centre, double-blind, study involved 259 patients with "bipolar 1" disorder. These individuals were randomly assigned to receive either 1-6 mg of Risperdal daily (average dose was 4.1 mg) or placebo for three weeks. Patients' symptoms were assessed at the beginning of the research using the YMRS (Young Mania Rating Scale, a widely accepted measurement of manic symptoms), and the primary measure of efficacy was the average change in the YMRS score by the end of the study. Patients taking Risperdal in the study experienced improvements in their YMRS scores that were significantly greater than those for individuals who received placebo. Significant improvements were observed with Risperdal as early as day three and were sustained throughout the trial. In addition, significant symptom relief was shown using another assessment tool, the Clinicians' Global Impression-Severity scale. Physicians using this device reported that individuals receiving Risperdal improved twice as much as patients who took placebo. More Risperdal-treated patients completed the study than those who took placebo. Janssen Pharmaceutica Products LP, a wholly owned subsidiary of Johnson & Johnson, has a long track record in developing and marketing treatments for central nervous system disorders. Based in Titusville, NJ, Janssen Pharmaceutica Products' other speciality areas include pain management, treatment of fungal infections and therapy for gastrointestinal conditions. Copyright 2002. All Rights Reserved. Financial Times Information Limited - Asia Africa Intelligence Wire http://www.jnj.com <> << Copyright ©2002 Financial Times Limited, All Rights Reserved >>
16 Декабрь,2002 | Abbott Labs Says Study Favors Depakote Over Zyprexa
Dow Jones Business News via Dow Jones ABBOTT PARK, Ill. --Abbott Laboratories said its Depakote treatment for bipolar disorder has fewer side effects than Eli Lilly & Co.'s antipsychotic drug Zyprexa. Dow Jones Online News via NewsEdge Corporation : Dow Jones Business News via Dow Jones ABBOTT PARK, Ill. (Dow Jones)--Abbott Laboratories (ABT) said its Depakote treatment for bipolar disorder has fewer side effects than Eli Lilly & Co.'s (LLY) antipsychotic drug Zyprexa. In a press release Monday, Abbott said a study of 120 patients showed that the two drugs have similar efficacy in treating acute mania, but Depakote users reported fewer instances of weight gain, drowsiness, runny nose, speech disorder and swelling. Depakote, approved by the Food and Drug Administration in 1995, is the most prescribed treatment for mania, Abbott said. New York Stock Exchange-listed shares of Abbott recently traded at $39.95, down 53 cents, or 1.3%, on composite volume of 701,600 shares. Average daily volume is 4.5 million shares. -Kara Wetzel; Dow Jones Newswires; 201-938-5388 (END) Dow Jones Newswires 12-16-02 1105ET - - 11 05 AM EST 12-16-02 DJONviaNewsEdge <> << Copyright ©2002 Dow Jones and Company, Inc. >>
09 Декабрь,2002 | Women more prone to depression
Lahore Dec 04-PPI: Women in male-dominated society are more likely to suffer headache, gastric disturbance, loss of energy, loss of weight etc which has their roof cause in depression. In a press statement here on Wednesday a local clinical psychologist Mrs. Pakistan Press International via NewsEdge Corporation : Lahore Dec 04-PPI: Women in male- dominated society are more likely to suffer headache, gastric disturbance, loss of energy, loss of weight etc which has their roof cause in depression. In a press statement here on Wednesday a local clinical psychologist Mrs. Saima S. Qamar said the women were more likely to undergo depression, anxiety, feelings of insecurity and other physical manifestation of psychological problems as compared to men. "In a society like ours it is more important to identify the problems of the womenfolk and enable them to face these with confidence and courage," she added. She maintained that the women in our society were less exposed to society and "parents as well as society constantly make them conscious of their limited role which is coupled with inadequate education and ignorance on their social, legal and religious rights." She said over 80 percent population of the country resided in the rural areas where the availability of a qualified physicians and surgeons was doubtful then what to talk about the availability of psychological services. "Most of the women other than the non-availability of psychological facilities, have no conception about the origin of their psychological or psychiatric problems and visit general practitioners for various symptoms like headache, gastric disturbances, loss of energy, loss of weight which are related to psychiatric disorders," she observed. (THROUGH ASIA PULSE) 04-12 2002 <> << Copyright ©2002 Asia Pulse Pte Ltd. >>
09 Декабрь,2002 | Egis/Drug/SSSB -2/May Treat Depression As Well As Anxiety
Dow Jones Business News via Dow Jones BUDAPEST --Finnish pharmaceutical company Orion OYJ has confirmed that deramciclane, Hungarian drug maker Egis' new drug, is effective against depression as well as anxiety, Schroder Salomon Smith Barney said Monday. Dow Jones Online News via NewsEdge Corporation : Dow Jones Business News via Dow Jones BUDAPEST (Dow Jones)--Finnish pharmaceutical company Orion OYJ (Y.OYH) has confirmed that deramciclane, Hungarian drug maker Egis' (R.EGS) new drug, is effective against depression as well as anxiety, Schroder Salomon Smith Barney said Monday. Orion made the confirmation at a research and development day Dec. 3, SSSB said in a report. "In preclinical models, deramciclane showed potential against anxiety and depression," SSSB quoted Esa Heinonen, Orion's head of research and development as saying. "Preclinical data suggested deramciclane would have similar chances in depression as in anxiety," Heinonen added. Deramciclane is currently under phase III clinical testing as an anti-anxiety drug. Its effectiveness for depression is likely to be a major breakthrough for Egis. (MORE) Dow Jones Newswires 12-09-02 0726ET - - 07 26 AM EST 12-09-02 DJONviaNewsEdge <> << Copyright ©2002 Dow Jones and Company, Inc. >>
| Главная | Структура центра | История НЦПЗ | Совет молодых ученых | Костромские школы молодых ученых | Новости | Профсоюз | Правовые документы | Вакансии | О сайте | Научная работа | Научные отделы и лаборатории | Публикации сотрудников | Диссертационный совет | Авторефераты диссертаций | Музей НЦПЗ | Для научных сотрудников НЦПЗ | Центр коллективного пользования «Терапевтический лекарственный мониторинг» | Образовательная деятельность | Ординатура | Аспирантура | Дополнительное профессиональное образование | Студенческий научный кружок | Нормативные документы | Платные образовательные услуги | Информация для обучающихся в ординатуре и аспирантуре | Лечебный процесс | Клинические отделения | Условия и порядок стационирования | Прейскурант платных медицинских услуг | Перечень заболеваний | Отзывы о работе клиники | Клиника (фотогалерея) | Библиотека | Научная литература для специалистов | Материалы конференций | Авторефераты диссертаций | Пособия для врачей | Психометрические шкалы | Болезнь и творчество | Галерея | Журнал «Психиатрия» | Перечень тематических журналов, рекомендованных ВАК | Перечень тематических журналов в международных БД | РИНЦ | Russian Science Citation Index (RSCI) | Полезные ссылки | Журнал «Психиатрия» | Неспециалистам | Контакты